Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials - Université de Lorraine Access content directly
Journal Articles The Lancet Year : 2022

Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials

1 Amsterdam UMC - Amsterdam University Medical Center
2 University of Calgary
3 AZ Delta
4 Imelda General Hospital
5 Mount Sinai School of Medicine
6 UniSR - Universita Vita Salute San Raffaele = Vita-Salute San Raffaele University [Milan, Italie]
7 IRCCS San Raffaele Hospital
8 UWO - University of Western Ontario
9 Kyorin University School of Medicine [Tokyo, Japan]
10 University of Alberta
11 Bart's and The London School of Medicine and Dentistry
12 Mayo Clinic College of Medicine
13 IDIBAPS - Institut d'Investigacions Biomèdiques August Pi i Sunyer
14 CIBERehd - Centro de Investigación Biomédica en Red en el Área temática de Enfermedades Hepáticas y Digestivas
15 Clinic Barcelona Hospital Universitari
16 Service d'Hépato-gastro-entérologie [CHRU Nancy]
17 NGERE - Nutrition-Génétique et Exposition aux Risques Environnementaux
18 Inflammatory Bowel Disease Research Center [Shanghai]
19 Shanghai Jiao Tong University [Shanghai]
20 Institute of Digestive Disease, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China
21 The University of Chicago Medicine [Chicago]
22 UC San Diego - University of California [San Diego]
23 UKSH - University Medical Center of Schleswig–Holstein = Universitätsklinikum Schleswig-Holstein
24 CAU - Christian-Albrechts-Universität zu Kiel = Christian-Albrechts University of Kiel = Université Christian-Albrechts de Kiel
25 Abbvie Inc. [North Chicago]
26 AbbVie Deutschland GmbH & Co KG
27 KU Leuven - Catholic University of Leuven = Katholieke Universiteit Leuven
Filip Baert
  • Function : Author
Allen Lim
  • Function : Author

Abstract

Risankizumab, an interleukin (IL)-23 p19 inhibitor, was evaluated for safety and efficacy as induction therapy in patients with moderately to severely active Crohn's disease.
AbbVie.
No file

Dates and versions

hal-04165754 , version 1 (19-07-2023)

Identifiers

Cite

Geert d'Haens, Remo Panaccione, Filip Baert, Peter Bossuyt, Jean-Frederic Colombel, et al.. Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials. The Lancet, 2022, 399 (10340), pp.2015-2030. ⟨10.1016/S0140-6736(22)00467-6⟩. ⟨hal-04165754⟩
8 View
0 Download

Altmetric

Share

Gmail Mastodon Facebook X LinkedIn More